I Bought My Shares Back. A Very Bullish Trading Pattern
There is no doubt that the underwriters SHORTED a lot of stock TODAY in addition to their customers who were allocated stock at $11.50.
The fact that it held a little below $11 tells me that those with inside knowledge which includes MDs who are conducting the C-Pulse implants, are spreading the word of good results, and those buyers are taking up the HUGE SHORT SELLING of allocated stock
I've been trading the stock since I came to this board. Further, I'm discussing today's action. I averaged my buying today a little under $11.90. So I'm holding more than I sold yesterday.
The C-Pulse, if the CEO and published data are true, is a definite success within a large subset of Class 3 patients who number more than a million in just the USA. Unlike other Mechanical Circulatory Support Devices, the C-Pulse allows for a Pulsatile circulation as opposed to the HeartMate 2 (Thoratec) and the HVAD (Heartware) device which is continuous flow (CF). That feature, even by itself, provides a huge advantage over those other devices since it closely emulates how blood flows in humans. When you include a non-invasive non-blood-contacting simple non-invasive surgery, the C-Pulse shines. The final shoe to drop for the stock to reach the next level is that the data show efficacy.